2,800
Participants
Start Date
June 6, 2019
Primary Completion Date
November 30, 2026
Study Completion Date
March 31, 2027
Blood test: ClarityDX Prostate
PSA on patients who are suspected to have prostate cancer and will undergo a prostate biopsy. ClarityDX Prostate Risk Score will be compared with biopsy results to assess its predictive accuracy.
Johns Hopkins University, Baltimore
Prostate Cancer Centre, Calgary
Kipnes Urology Centre, Edmonton
Lead Sponsor
Collaborators (2)
Alberta Prostate Cancer Research Initiative, APCaRI
UNKNOWN
Prostate Cencer Centre, Calgary
UNKNOWN
Alberta Cancer Foundation
OTHER
Alberta Innovates Health Solutions
OTHER
Motorcycle Ride for Dad
UNKNOWN
University Hospital Foundation - The Kaye Fund Competition
UNKNOWN
Alberta Precision Laboratories
UNKNOWN
Kipnes Urology Centre
UNKNOWN
Nanostics
INDUSTRY